Skip to main content
Premium Trial:

Request an Annual Quote

Durin Technologies Closes $3.5M Funding Round

NEW YORK – Diagnostic firm Durin Technologies said Tuesday that it has closed a $3.5 million funding round led by Breakthrough Diagnostics.

Mullica Hill, New Jersey-based Durin said it will use the funds to support commercialization of diagnostic tests for Alzheimer's and Parkinson's disease and the development of additional diagnostics.

The funding follows Durin's appointment in November of Mert Sahin as CEO. Sahin previously led marketing for GE Healthcare's imaging business in the US and Canada and has also held roles at Roche Diagnostics, Eurofins Genomics, Thermo Fisher Scientific and Dalan Animal Health.

Durin's work has focused on the use of autoantibodies for disease detection. The company's Alzheimer's diagnostic, called Duritect-AD, measures the levels of eight autoantibodies in blood to assess the likelihood that a person has Alzheimer's disease.

“With this latest funding, we are poised to bring our tests into the market and move closer to satisfying the demands of physicians, patients, and their loved ones with fast, easy-to-understand, and reliable diagnosis of life-altering diseases," Sahin said in a statement.